Metastatic basal cell carcinoma with a high tumor mutational burden that achieved complete response with pembrolizumab

Int J Dermatol. 2023 Feb;62(2):e79-e80. doi: 10.1111/ijd.16245. Epub 2022 May 12.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Carcinoma, Basal Cell* / drug therapy
  • Carcinoma, Basal Cell* / genetics
  • Humans
  • Remission Induction
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / genetics

Substances

  • pembrolizumab
  • Antibodies, Monoclonal, Humanized